AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Ibrexifunder Is FDA Approved to Treat Volovaginal Candidasis
Ibrexifunder is FDA approved to the treatment of volovaginal candidiasis, specifically in adult and post-menar goal of emails. It inhibits one, three beta D glue pan synthase which sounds an awful lot like cannons but it does interact with a unique binding site. There are no adjustments for renal or hepatic dysfunction, but there are significant drug interactions.